Title:
POLYMORPH OF EGFR INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2023/061433
Kind Code:
A1
Abstract:
Provided is a compound of formula (A), N-(6-((5-bromo-2-((6-isopropyl-8-methoxy-3-methyl-3,4,5,6-tetrahydrobenzo[b]pyrazolo[4,3-D]aza-9-yl)amino)-pyrimidin-4-yl)amino)-quinoxaline-5-yl)methanesulfonamide, and a compound of formula (I), and polymorphs thereof. The provided polymorphs have a good chemical stability, physical stability and low hygroscopicity, are less affected by heat, humidity and illumination, and are convenient to store and prepare.
Inventors:
SUN ZHUANG (CN)
LI YUJIE (CN)
JIANG CHEN (CN)
DUAN JIE (CN)
FU QIANG (CN)
XIN LIANXIN (CN)
ZHENG SHANSONG (CN)
DENG WEI (CN)
LI LEILEI (CN)
LI YUJIE (CN)
JIANG CHEN (CN)
DUAN JIE (CN)
FU QIANG (CN)
XIN LIANXIN (CN)
ZHENG SHANSONG (CN)
DENG WEI (CN)
LI LEILEI (CN)
Application Number:
PCT/CN2022/125056
Publication Date:
April 20, 2023
Filing Date:
October 13, 2022
Export Citation:
Assignee:
QILU PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D519/00; A61K31/55; A61P35/00
Domestic Patent References:
| WO2021190417A1 | 2021-09-30 | |||
| WO2020216371A1 | 2020-10-29 | |||
| WO2021018009A1 | 2021-02-04 | |||
| WO2017220007A1 | 2017-12-28 | |||
| WO2021208918A1 | 2021-10-21 | |||
| WO2021238827A1 | 2021-12-02 |
Attorney, Agent or Firm:
MERITS IP LTD. (CN)
Download PDF:
Previous Patent: PYRIMIDINE TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF
Next Patent: USE OF TRICYCLIC COMPOUND
Next Patent: USE OF TRICYCLIC COMPOUND